RBC Capital Says This Dystrophy Stock 'Is Worth A Look'
RBC Capital says Edgewise Therapeutics Inc's (NASDAQ:EWTX) interim results from the ARCH study of EDG-5506 in Becker Muscular Dystrophy (BMD) improve reward/risk into October functional readout at 15 mg, which can help further de-risk the asset into the phase 2 BMD and Duchenne muscular dystrophy (DMD) studies. The analysts believe stable patient NSAAs in October…
Benzinga ·
Benzinga
